Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW5004 in Combination With Anti-Tumor Therapy in Advanced Prostate Cancer
NCT07730580Phase 2Not yet recruiting
- Sponsor
- Evopoint Biosciences
- Start
- Jul 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 2 trial of igermetostat in prostate cancer (PCa), sponsored by Evopoint Biosciences. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
igermetostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07730580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730580.